u/HydraKing3

[ Removed by Reddit on account of violating the content policy. ]

[ Removed by Reddit on account of violating the content policy. ]

[ Removed by Reddit on account of violating the content policy. ]

Three catalysts remaining this year, each with a different weight:

1. FDA IND Clearance — Expected Q2 2026 Allows Phase 2 to include US clinical sites. This is largely administrative at this stage — IND clearance for a drug that's already completed Phase 1 and Phase 1b elsewhere is not a high-risk event, but it's a gating item for the US Phase 2 timeline. If it gets delayed it pushes everything else back.

2. Phase 2 Initiation — Expected Q3 2026 This is the most visible near-term milestone. A Phase 2 start confirms the program is advancing and tends to generate attention for clinical-stage names. It doesn't tell you anything about efficacy yet but it moves the story forward concretely.

3. Full Phase 1b Results — Expected Q4 2026 This is the most analytically meaningful catalyst of the three. The full dataset from the nine-month extension will include longer-term biomarker and clinical data with the complete 16-participant population. This is when you get the most complete picture of GT-02287's disease-modifying signal before Phase 2 readouts become available.

There's also a presentation at the 3rd International GBA1 Meeting in Phoenix later in May where additional Phase 1b data is expected to be shared. Smaller near-term event but worth watching for any incremental data.

The risk sitting alongside all of this: $16.5M in cash as of March 31, burning roughly $4-5M per quarter before Phase 2 costs kick in. A capital raise is likely somewhere in this timeline. Dilution is a real consideration alongside every catalyst above.

This is not financial advice!!! It's important to do your own DD before making any investment decisions. - 1, 2, 3

Most of the GANX thesis lives or dies on GT-02287. Here's a clear-eyed look at what the clinical data actually shows versus what's still unproven.

What's been demonstrated so far in Phase 1b:

Central nervous system target engagement — meaning the drug is reaching the brain and hitting the intended target. That's a necessary condition for efficacy but not sufficient on its own.

GluSph reduction of 81% in CSF among participants with elevated baseline levels after 90 days. GluSph (glucosylsphingosine) is a lipid substrate that accumulates when GCase enzyme function is impaired. Reducing it is the intended mechanism. An 81% reduction in the relevant subgroup is a meaningful biomarker signal — but it's in a subgroup, not the full trial population.

MDS-UPDRS scores stable over 150 days. MDS-UPDRS is the standard clinical rating scale for Parkinson's motor and non-motor function. Stability in a progressive disease is actually a positive signal — Parkinson's typically worsens over time, so holding steady suggests potential disease modification. However this is Phase 1b in a small population. Stability at this scale does not confirm disease modification — it's suggestive, not conclusive.

DDC levels decreased in the elevated GluSph subgroup. DOPA decarboxylase is an enzyme involved in dopamine production. Its reduction following treatment is another downstream biomarker that aligns with the proposed mechanism.

What hasn't been shown yet:

A placebo-controlled comparison. Phase 1b has no control arm. You don't know what MDS-UPDRS scores would have done without the drug in this specific population over the same period.

Long-term durability beyond 150 days in most participants. The nine-month extension completes in October 2026. Full Phase 1b results expected Q4 2026.

Efficacy in a larger, randomized population. That's what Phase 2 is for, expected to begin Q3 2026 pending FDA IND clearance in Q2 2026.

The second candidate — GT-04686: A newer GCase modulator identified through their Magellan platform. Described as ready for IND-enabling studies. Earlier stage than GT-02287 but uses the same mechanism and platform. Optionality asset at this point rather than near-term catalyst.

Bottom line on the science: The Phase 1b data is genuinely encouraging for a mechanism-based drug — target engagement, relevant biomarker reduction, and clinical stability in a small progressive disease population. The honest limitation is that none of it is placebo-controlled and the population is small. Phase 2 is what will actually answer the efficacy question.

This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3

Most of the GANX thesis lives or dies on GT-02287. Here's a clear-eyed look at what the clinical data actually shows versus what's still unproven.

What's been demonstrated so far in Phase 1b:

Central nervous system target engagement — meaning the drug is reaching the brain and hitting the intended target. That's a necessary condition for efficacy but not sufficient on its own.

GluSph reduction of 81% in CSF among participants with elevated baseline levels after 90 days. GluSph (glucosylsphingosine) is a lipid substrate that accumulates when GCase enzyme function is impaired. Reducing it is the intended mechanism. An 81% reduction in the relevant subgroup is a meaningful biomarker signal — but it's in a subgroup, not the full trial population.

MDS-UPDRS scores stable over 150 days. MDS-UPDRS is the standard clinical rating scale for Parkinson's motor and non-motor function. Stability in a progressive disease is actually a positive signal — Parkinson's typically worsens over time, so holding steady suggests potential disease modification. However this is Phase 1b in a small population. Stability at this scale does not confirm disease modification — it's suggestive, not conclusive.

DDC levels decreased in the elevated GluSph subgroup. DOPA decarboxylase is an enzyme involved in dopamine production. Its reduction following treatment is another downstream biomarker that aligns with the proposed mechanism.

What hasn't been shown yet:

A placebo-controlled comparison. Phase 1b has no control arm. You don't know what MDS-UPDRS scores would have done without the drug in this specific population over the same period.

Long-term durability beyond 150 days in most participants. The nine-month extension completes in October 2026. Full Phase 1b results expected Q4 2026.

Efficacy in a larger, randomized population. That's what Phase 2 is for, expected to begin Q3 2026 pending FDA IND clearance in Q2 2026.

The second candidate — GT-04686: A newer GCase modulator identified through their Magellan platform. Described as ready for IND-enabling studies. Earlier stage than GT-02287 but uses the same mechanism and platform. Optionality asset at this point rather than near-term catalyst.

Bottom line on the science: The Phase 1b data is genuinely encouraging for a mechanism-based drug — target engagement, relevant biomarker reduction, and clinical stability in a small progressive disease population. The honest limitation is that none of it is placebo-controlled and the population is small. Phase 2 is what will actually answer the efficacy question.

This is not financial advice!!! It’s important to do your own DD before making any investment decisions. - 1, 2, 3

$GANX Q1 seemed fairly standard for a clinical-stage biotech. The EPS beat itself was minimal, so I don’t think that’s what really mattered here.

Main takeaways for me:

• Loss widened year over year
• Operating expenses continued climbing
• Management kept the same regulatory and clinical timelines in place

They’re still guiding for:

• IND clearance in Q2
• Phase 2 start in Q3
• Additional Phase 1b data later this year

The company also highlighted stable MDS-UPDRS scores in the extension study again, although I’d still be careful drawing major conclusions from a dataset this small.

Overall, this still looks like a name that will trade mostly on future clinical results and FDA progress rather than quarterly earnings numbers.

Remember to do your own due diligence before committing to any trades! 1, 2, 3

Caught the VTIX webinar replay and a few things stood out.

CEO addressed the drop directly. Said the stock getting cut in half in a week was “gut wrenching.” No company-specific news. He pointed to increased short activity after being included in a sub-$10 stock list. Also clarified his 10b5-1 plan. Sold 500k shares out of ~4.5M. Plan is now done.

On the business side:

Consumer
Omni One is still the core product. Direct-to-consumer, priced roughly $2.1k to $3.5k depending on bundle. Targeting ~40% gross margin on hardware. Recurring comes from games and subscriptions.
Capacity isn’t the issue. Facility is ~40k sq ft, ~20 staff. Said they could get to ~3,000 units/month with a second shift, which they framed as ~ $100M annualized potential. The constraint right now is demand.

Defense
This is where most of the focus seems to be. Activity across all four branches. Marine Corps project with 4-person simulators, first delivery expected Q4. If it works, could expand to ~20 training sites.
Also pushing Virtual Terrain Walk, using AI to turn real environments into VR for planning and training.

M&A
New committee targeting defense training companies doing ~$10M–$50M in revenue. Idea is to get access to contract vehicles and recurring revenue faster instead of building it all organically.

Other
Some enterprise use cases mentioned, including a university project using the system to teleoperate a humanoid robot.

They’re guiding year-end results in the second half of June.

Stock is still sitting low $3s after the drop. Takeaway for me is pretty straightforward.
Consumer side depends on demand showing up.
Defense side depends on contracts actually scaling beyond pilot programs.
M&A could speed things up, but also adds another layer.

Curious if anyone else listened and how realistic the defense ramp looks near term. 1, 2, 3

[ Removed by Reddit on account of violating the content policy. ]

$VTIX’s new article reads less like a growth update and more like an acknowledgment that the current model isn’t scaling.

Virtuix (VTIX) generating ~$4.5M in revenue while trying to position itself as a defense training platform creates a mismatch. Forming a committee to pursue acquisitions is essentially a way to bridge that gap quickly rather than waiting on organic traction from pilots and small deployments.

The specific criteria they’re targeting is the most useful signal. Companies with $10M–$50M in recurring defense revenue and existing contract vehicles. That suggests two things:

1. They’re prioritizing revenue stability over early-stage tech
2. They recognize that procurement access is a bottleneck, not just product adoption

In defense, getting onto the right contract vehicles can take years. Buying a company that already has that access is often faster than trying to build it internally. So this is less about expanding capabilities and more about plugging into existing revenue streams.

The issue is relative size. They’re a ~$116M market cap company looking at targets that could be multiples of their own revenue. That introduces a few structural constraints:

• Any meaningful acquisition likely requires external financing
• Equity issuance at current levels is dilutive given how far the stock has fallen
• Debt adds pressure to a business that isn’t generating consistent cash flow

So even if they identify a target, the path to closing a deal isn’t straightforward.

CEO Jan Goetgeluk calling potential deals “accretive” hinges entirely on valuation and structure. At a high revenue multiple, in theory they could acquire lower-multiple defense contractors and improve blended metrics. But that only works if the deal is actually completed on favorable terms and the acquired revenue holds post-integration.

There’s also a strategic tension. Their current positioning is built around VR and AI-driven training systems. The acquisition targets they’re describing sound more like traditional defense contractors with established revenue. That raises the question of whether Virtuix becomes a hardware/software layer on top of an acquired base, or if the acquisition effectively becomes the core business.

The recent pattern of announcements adds context. They’ve shown consistent activity across defense branches, but mostly at the pilot or early deployment level. That builds credibility, but not scale. This acquisition strategy looks like an attempt to skip the slow middle phase where pilots convert into large contracts.

For now, this is still preliminary. A committee reviewing “advanced-stage discussions” doesn’t guarantee anything closes. Until there’s a signed deal with disclosed terms, this doesn’t change the financial profile of the company.

What it does change is the framing. Instead of being evaluated purely on its existing VR business, Virtuix is signaling that future performance may depend on capital allocation decisions and M&A execution. That shifts the risk from just product adoption to deal-making and integration. 1, 2, 3

I’ve been digging through a few Parkinson’s-focused biotechs and the spread between them is pretty wide. Same general space, but very different setups in terms of stage, funding, and what could go wrong.

Gain Therapeutics (GANX)
Small, early-stage, based in Bethesda. Their main asset, GT-02287, is in Phase 1b. Early signals showed some biomarker shifts and hints of motor stabilization, but it’s still very early and far from de-risked. They’ve had support from the Michael J. Fox Foundation, which helps credibility a bit. Financially, though, they’re not in a strong position. No revenue and burning around $20M a year, so they’ll almost certainly need to raise before getting through the next phase. They do control global rights through 2038, which is a plus if things progress. Phase 2 is expected to kick off in Q3. Market cap sits around $88M.

Annovis Bio (ANVS)
More advanced clinically, but with more pressure underneath. Buntanetap is already in Phase 3 for Alzheimer’s, with a Parkinson’s study running alongside it. That sounds attractive at a glance since it’s closer to a potential inflection point. The issue is the balance sheet. No revenue, about a $28.9M net loss, plus a recent CFO exit and going concern language. It’s one of those situations where the science might be further along, but the company itself looks fragile. Market cap is roughly $64M.

Anavex Life Sciences (AVXL)
This one is in a different position financially. Around $131.7M in cash, no debt, and a runway that likely stretches a few years. Pipeline is broader too, covering Alzheimer’s, Parkinson’s, and Rett syndrome with blarcamesine and ANAVEX 3-71. Still pre-revenue, still losing money, but not under immediate pressure to raise. The main issue here is regulatory. They’ve already run into setbacks, including a negative opinion from Europe’s CHMP on their lead drug. So less concern about survival, more about whether the programs actually clear regulatory hurdles. Market cap is about $324M.

Net of it:

• GANX is early and speculative, with financing risk front and center
• ANVS is further along clinically but looks stretched financially
• AVXL has time on its side, but still needs to prove it can get through regulators

They’re all viable in their own way, but each one leans into a different type of risk. Just depends which one you’re more comfortable underwriting. 1, 2, 3

Virtuix (VTIX) announced a Marine Corps–related training project, but the interesting part is less the headline and more how the structure of the deal differs from prior wins.

They’re working with KBR under the Marine Corps Training and Education Command to deploy a four-unit Omni One setup. The systems are networked so a full fire team can train together in the same virtual environment. That’s a step up from single-unit placements because it starts to test coordination, not just individual movement or immersion.

From a capability standpoint, that matters. Most of the earlier placements (West Point, Air Force Academy, university research) were closer to evaluation or exposure. This is closer to an operational use case, even if still early. The inclusion of a trainer workstation for scenario design and after-action review also suggests they’re trying to fit into an actual training workflow, not just demonstrate hardware.

That said, it still reads like a pilot. Four units is enough to test viability, not enough to signal budget-level adoption. The key variable is what happens after the Q4 delivery and assessment period. Defense procurement tends to move slowly, and scaling typically requires validation across multiple criteria: effectiveness vs. existing training methods, integration with current systems, and cost justification.

The “deja vu” framing from the retired Colonel is directionally aligned with how the military evaluates simulation tech. If it meaningfully improves familiarity and decision-making under stress, it has a case. If it’s viewed as supplemental or non-essential, it stays limited.

On the pattern of announcements, there is a shift. Prior updates were fragmented. This starts to look like a sequence: Navy development agreement, Marine Corps-related activity, now a more integrated training setup. The question is whether that reflects real traction or just a series of small, unrelated engagements being grouped into a narrative.

Market reaction so far hasn’t priced in much of that distinction. The stock has been weak, which suggests investors are either discounting the near-term revenue impact or waiting for something more concrete, like follow-on orders or disclosed contract values.

The upcoming May 8 webinar with CEO Jan Goetgeluk is probably where more clarity could come from. Specifically:

• whether this project has defined expansion criteria
• any indication of pipeline beyond pilot programs
• and how they’re thinking about defense as a revenue segment vs. just a validation channel

So the takeaway isn’t that this is a breakout contract. It’s that this is the first announcement that starts to test whether their product can function in a coordinated, semi-operational setting. Whether that turns into something larger depends entirely on what comes after the evaluation phase. 1, 2, 3

Not fully there yet, but still showing up consistently.

Virtuix (VTIX) is getting another TV spot this weekend. They’re part of a New to The Street episode airing Saturday on Bloomberg, with the segment focused on VR military simulation for training and mission rehearsal.

That lines up with what they’ve been leaning into lately. Defense has been the main thread, with the Navy agreement, Marine Corps purchase, and demos in front of senior officials. The TV segment doesn’t really change the story, it just reinforces it.

They’ve been on this program a few times now, along with spots on Fox Business. It’s sponsored programming, so it’s more about visibility than validation. Still, for a small cap, it keeps the name circulating.

There are a couple other events stacked around it too. Market Movers Summit in New York on May 5th and their investor webinar on May 8th. Pretty tight window of appearances.

The pattern is just continued exposure. TV segments, events, demos. They’re staying visible even without a major new update.

Whether that translates into anything beyond awareness is harder to tell. 1, 2, 3

went through GPOX financials

revenue around $4.7M
gross profit about $1.13M

https://preview.redd.it/tf9yy18uadyg1.png?width=1339&format=png&auto=webp&s=c9f72f46f927983dfd48d03835504e99e7bad2ca

so gross margin is improving

operating expenses still over $4.3M
so most of that gross profit gets eaten up right away

loss from operations roughly $3.2M
net loss about $4.3M

so they’re still losing close to what they bring in

gap between revenue and profitability is still pretty wide

cost side did come down a bit
which is why losses narrowed

but it’s not a small adjustment needed to get to breakeven

bigger issue is cash

last filing had it basically near zero
so they’ve been funding through notes and equity

which means they need either
a) revenue to scale quickly
or
b) continued external funding

otherwise timing becomes a factor

numbers are moving in the right direction
just not there yet 1, 2, 3

they’re basically in the convenience store distribution lane
DSD model, so getting product directly onto shelves instead of going through layers

what they’re trying to fix is pretty simple
stores run out of stuff → lost sales
their pitch is managing that better through their own system

PRISM+ is what they built in house
handles routes, inventory levels, driver tracking, store side reporting
so instead of guessing what each location needs, it’s supposed to be data driven

the part I keep going back to is how fragmented that space is
a lot of smaller distributors, a lot of inefficiency
so the idea is if you can run it tighter, you can take share over time

they’ve shown growth the past few years
but starting from a small base so it’s not as straightforward as it looks

recent move was launching that ad campaign
going after regional chains with like 5–35 stores
which feels more like “figure it out at a smaller scale first” vs trying to land huge accounts

on the other side
cash is still tight
they’ve been funding through notes and equity

so it kind of comes down to execution
if the system actually works at store level and they can roll it out cleanly, there’s a path

if not, it’s just another distributor story with higher costs

Saw this come up on GANX and figured I’d flag it.

They’ve got an oral presentation scheduled at the International GBA1 Meeting in Phoenix next month. For anyone new, this is a clinical stage biotech working on Parkinson’s, with a focus on the GBA1-related pathway.

The presentation is May 22nd and it’s an update on their lead candidate GT-02287. Their Chief Medical Officer is presenting, and it’s part of a session focused on ongoing pharma research and trials in this area.

They’re also attending the World Parkinson’s Congress right after, same city, a few days later.

From what I’ve seen, they already shared Phase 1b data earlier this year with some biomarker changes and stabilization signals. Still early though, and Phase 1 is mainly about safety, so I’m not reading too much into it yet.

I think the main thing here is just continued presence at these conferences. For biotech, that seems to matter for visibility with researchers and clinicians, even if it doesn’t immediately translate into anything tangible.

They’ve also had backing from groups like the Michael J. Fox Foundation, which at least suggests the program has gotten some level of external interest.

Still very early stage and definitely speculative. A lot depends on how things progress in later trials.

Not financial advice. Just something I’m keeping an eye on. 1, 2, 3

Anyone else following this or familiar with the GBA1 angle in Parkinson’s research?